Ralf Otto Named COO at Rentschler Biopharma

News
Article

Biopharm industry veteran Ralf Otto named to lead development and manufacturing at Rentschler Biopharma.

Rentschler Biopharma, a contract development and manufacturing organization for biopharmaceuticals, appointed Ralf Otto as chief operating officer (COO), effective Feb. 1, 2018, succeeding Thomas Siklosi, who will move to Dr. Rentschler Holding GmbH & Co. KG, according to a Jan. 31, 2018 press statement.

Otto-who will be responsible for development, manufacturing, and quality management-has more than 20 years at senior positions in industry and management consulting and has overseen all stages of the biopharmaceutical value chain.

Most recently, he was a Partner at McKinsey & Company.  Previously, he held executive positions in cell biology and biopharmaceutical manufacturing at Boehringer Ingelheim and as vice-president Biopharma Operations, Otto headed the Boehringer site in Fremont, CA.

Source:  Rentschler Biopharma SE

 

 

Recent Videos
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Related Content